Autologous haematopoietic stem cell transplantation revolutionized the treatment of severe systemic sclerosis as the first therapy able to induce long-term remission in this relentlessly fibrosing disease. Nevertheless, questions remain about patient selection, conditioning, and how this treatment fits into the evolving immune-modifying therapeutic landscape. The field should move beyond standardization towards precision therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Bruera, S. et al. Stem cell transplantation for systemic sclerosis. Cochrane Database Syst. Rev. 7, CD011819 (2022).
Henes, J. et al. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. Haematologica 106, 375–383 (2021).
Alexander, T. et al. Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee. Bone Marrow Transplant. 60, 1451–1464 (2025).
Del Papa, N. et al. Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation. Bone Marrow Transplant. 60, 1537–1540 (2025).
Spierings, J. et al. Management of disease progression after autologous hematopoietic stem cell transplantation in systemic sclerosis: Results from an international questionnaire-based study. Semin. Arthritis Rheum. 71, 152638 (2025).
Kawashima-Vasconcelos, M. Y., Santana-Gonçalves, M., Zanin-Silva, D. C., Malmegrim, K. C. R. & Oliveira, M. C. Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis. Front. Immunol. 13, 941011 (2022).
Bankamp, L. et al. Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome. Rheumatology 62, 2168–2177 (2023).
Chiu, Y. H. et al. Anti-thymocyte globulin exposure in patients with diffuse cutaneous systemic sclerosis undergoing autologous haematopoietic stem cell transplantation. J. Scleroderma Relat. Disord. 8, 241–246 (2023).
Spierings, J. et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open 18, e044483 (2021).
Distler, J. H. W. et al. Emerging therapies for the treatment of systemic sclerosis. Nat. Rev. Rheumatol. 21, 612–625 (2025).
Acknowledgements
The authors thank J.M. van Laar for discussing and proofreading this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Schimmel, C., Spierings, J. The future of autologous stem cell transplantation in systemic sclerosis. Nat Rev Rheumatol (2025). https://doi.org/10.1038/s41584-025-01341-7
Published:
Version of record:
DOI: https://doi.org/10.1038/s41584-025-01341-7
